Aaron Keshen

Dr. Aaron Keshen


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in International Journal of Eating Disorders
Verified
Journal Article
Open access
SBSara Bartel
Sara Bartel
SMSusan L. McElroy
Susan L. McElroy
DLDanielle Levangie
Danielle Levangie
AKAaron Keshen
Aaron Keshen
Glucagon‐like peptide‐1 receptor agonists (GLP‐1As) are being used as approved or off‐label treatments for weight loss. As such, there has been increasing concern about the potential for GLP‐1As to impact eating disorder (ED) symptomatology. This article seeks to (1) review the current state of knowledge regarding GLP‐1As and ED symptomatology; (2) provide recommendations for future research; and (3) guide ED clinicians in how to discuss GLP‐1As in clinical practice. Although evidence is limited, it is possible that GLP‐1As could exacerbate, or contribute to the development of, ED pathology and negatively impact ED treatment. Preliminary research on the use of GLP‐1As to treat binge eating has been conducted; however, studies have design limitations and additional research is needed. Therefore, at the current time there is not sufficient evidence to support the use of GLP‐1s to treat ED symptoms. In summary, more research is required before negative or positive conclusions can be drawn about the impact of GLP‐1As on EDs psychopathology. Herein, we provide specific recommendations for future research and a guide to help clinicians navigate discussions with their clients about GLP‐1As. A client handout is also provided.Public Significance: Despite glucagon‐like peptide‐1 receptor agonists (GLP‐1As; e.g., semaglutide) increasingly being the topic of clinical and public discourse, little is known about their potential impact on ED symptoms. It is possible that GLP‐1As could maintain, worsen, or improve ED symptoms. This article reviews the limited literature on GLP‐1As and ED symptoms, recommends future research, and provides clinicians with a guide for discussing GLP‐1As with ED clients.

30 November 2021 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
AKAaron Keshen
Aaron Keshen
SBSara Bartel Ba
Sara Bartel Ba
GFGuido Frank
Guido Frank
NSNils Erik Svedlund
Nils Erik Svedlund
ANAbraham Nunes
Abraham Nunes
SMSusan L. McElroy
Susan L. McElroy

12 February 2020 in European Eating Disorders Review
Verified
Journal Article
Closed access
PDF file
AKAaron Keshen
Aaron Keshen
THThomas Helson
Thomas Helson
SASarrah Ali
Sarrah Ali
LDLaura Dixon
Laura Dixon
JTJenna Tregarthen
Jenna Tregarthen
JTJoel Town
Joel Town

3 February 2021 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
AKAaron Keshen
Aaron Keshen
LDLaura Dixon
Laura Dixon
SASarrah I. Ali
Sarrah I. Ali
THThomas Helson
Thomas Helson
ANAbraham Nunes
Abraham Nunes
SMSusan L. McElroy
Susan L. McElroy

23 January 2017 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AKAaron Keshen
Aaron Keshen
THThomas Helson
Thomas Helson

7 April 2021 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
SASarrah I. Ali
Sarrah I. Ali
EBEmma Bodnar
Emma Bodnar
SGSusan Gamberg
Susan Gamberg
SBSara J. Bartel Ba
Sara J. Bartel Ba
GWGlenn Waller
Glenn Waller
AKAaron Keshen
Aaron Keshen